Pear oncology. Omada schizophrenia. Noom's $247M.

Issue 035. Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 62 percent open rate. Here's what's happening this week:

I'm working on the definitive Omada Health report this month. Hit reply to shoot me over any questions, leads or rumors you'd like me to run down while I'm in the homestretch of the research phase here.
The HHS Office of the National Coordinator for Health Information Technology posted a draft of its federal health IT strategic plan for 2020-2025. One line on page 14 caught the eye of a few people working in digital therapeutics: "Advance use of evidence-based digital therapeutics as treatment options for patients to prevent, manage, and treat conditions through smartphones, tablets, and other personal devices."
In other federal government news: The Agency for Healthcare Research and Quality (AHRQ) just

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Pear oncology. Omada schizophrenia. Noom’s $247M.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

Pear oncology. Omada schizophrenia. Noom’s $247M.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.